Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPB-01 for Steroid-Refractory NMOSD Myelitis
NCT01845584Phase 2Completed
- Sponsor
- Nihon Pharmaceutical
- Start
- May 2013
- Primary completion
- Aug 2015
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, PEGylated Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of NPB-01-ME in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Nihon Pharmaceutical. Started May 2013; status: completed.
02
Drugs
NPB-01-ME
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT01845584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01845584.